FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) has earned an average rating of “Reduce” from the six brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $18.75.
Separately, StockNews.com started coverage on shares of FibroGen in a research note on Friday, December 8th. They set a “hold” rating for the company.
FibroGen Stock Down 0.4 %
Institutional Trading of FibroGen
Hedge funds have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its holdings in shares of FibroGen by 49.7% during the third quarter. Assenagon Asset Management S.A. now owns 2,226,857 shares of the biopharmaceutical company’s stock worth $1,922,000 after buying an additional 739,166 shares in the last quarter. State of New Jersey Common Pension Fund D increased its holdings in shares of FibroGen by 31.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 138,888 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 33,010 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of FibroGen during the third quarter worth approximately $37,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of FibroGen by 216.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 293,612 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 200,883 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of FibroGen by 498.8% during the third quarter. SG Americas Securities LLC now owns 62,710 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 52,237 shares in the last quarter. Institutional investors and hedge funds own 78.34% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
- Five stocks we like better than FibroGen
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 attractive stocks that insiders are buying
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Invest in Esports
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.